The Top 5 Analyst Questions From Merck’s Q1 Earnings Call

Merck’s first quarter results were shaped by robust momentum in its oncology and animal health divisions, as well as meaningful contributions from recent product launches. Management highlighted the continued growth of KEYTRUDA, particularly in metastatic and earlier-stage cancers, and emphasized rising demand for WINREVAIR and WELIREG within the broader oncology portfolio. The company also pointed to key regulatory and product milestones, such as the FDA approval of IDVYNSO for HIV and the introduction of NUMELVI in animal health, as essential to this quarter’s performance.

Is now the time to buy MRK? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Merck’s Q1 Earnings Call

• Carter Gould (Cantor): Asked about dosing frequency and commercial potential for MK-3000 in retinal vascular disease. Dr. Dean Li, President of Research Labs, explained that initial focus is on 4-week dosing for regulatory purposes but confirmed that other dosing intervals are under evaluation.
• Jason Gerberry (Bank of America): Questioned if recent WELIREG trial results imply risks for other studies. Li responded that negative read-through is not expected and expressed confidence in upcoming readouts for WELIREG combinations.
• Asad Haider (Goldman Sachs): Asked about future business development focus. CEO Robert Davis emphasized science-driven acquisitions in oncology, immunology, and cardiometabolic, while clarifying that deal size could range broadly depending on opportunity.
• Daina Graybosch (Leerink): Sought clarification on the global relevance of China-based sac-TMT trial results. Li explained that while regional differences exist, Merck is closely monitoring these findings as they inform global development strategies.
• Steve Scala (TD Cowen): Inquired about the FDA review process for enlicitide and titration protocol. Li detailed the rolling submission process and ongoing discussions with the FDA about dosing and labeling considerations.

Catalysts in Upcoming Quarters

Looking forward, our analysts will be monitoring (1) the pace and uptake of new product launches, especially in oncology and specialty medicines, (2) progress toward key regulatory approvals and Phase III readouts for late-stage pipeline assets, and (3) the integration and performance of recently acquired or partnered assets such as TERN-701. Execution on commercial expansion and the impact of AI partnerships will also be key areas of focus.

Merck currently trades at $113.96, up from $110.95 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.